Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02633540 · ClinicalTrials.gov registry record · Phase 2

Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

A Phase 2 study, sponsored by Fox Chase Cancer Center.

Terminated
Registry status
Phase 2
Development phase
2
Enrollment target

NCT02633540: Clinical Trial Phase 2 study, sponsored by Fox Chase Cancer Center.

NCT02633540 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02633540, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
2 participants
Enrollment target

Study Summary

The aim of this study is to define a new treatment technique for T1a larynx cancer that maintains excellent local control with less extensive radiation fields. It is thought that this will lead to patients having fewer changes to their voice and a higher quality of life after treatment when compared to the current standard treatment.

Primary Outcome

Demonstrate a 50% improvement in the VHI (voice handicap index) score at 24 months after the completion of therapy IMRT for T1a/T2a larynx cancer

Interventions

  • RADIATION IMRT Radiation

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2015-11-16
Est. Completion 2018-05
Phase Phase 2
Fox Chase Cancer Center

183 total trials

Why NCT02633540 stopped before completion

NCT02633540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which IMRT Radiation is the first listed.

NCT02633540 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02633540 about?

NCT02633540 is a clinical study titled "Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function". The aim of this study is to define a new treatment technique for T1a larynx cancer that maintains excellent local control with less extensive radiation fields. It is thought that this will lead to patients having fewer changes to their voice and a higher quality of life after treatment when compared...

What is the current status of trial NCT02633540?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-11-16. Estimated completion is 2018-05.

What interventions are being tested in trial NCT02633540?

The interventions under investigation include: IMRT Radiation (RADIATION).

Who is sponsoring clinical trial NCT02633540?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02633540's enrollment target sits among peer trials

2 2001st of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02633540, the US trial registry maintained by the National Library of Medicine. NCT02633540 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.